# Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

> **NCT05585606** · PHASE2 · COMPLETED · sponsor: **Silver Creek Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Acute Ischemic Stroke (AIS)

## Interventions

- **DRUG:** Placebo
- **DRUG:** scp776 (1.9 mg/kg)
- **DRUG:** scp776 (3.8 mg/kg)
- **DRUG:** scp776 (4.8 mg/kg)
- **DRUG:** scp776 (all dose levels)

## Key facts

- **NCT ID:** NCT05585606
- **Lead sponsor:** Silver Creek Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-19
- **Primary completion:** 2025-09-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05585606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05585606, "Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05585606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*